1. Analyst View
2. The Global Obesity Epidemic
2.1 Defining Obesity
2.2 Prevalence of Obesity
2.3 The Cost of Obesity
2.4 Obesity is Linked to Higher Rates of Chronic Conditions
2.5 Obese Spend Significantly Higher on Healthcare
3. Available Weight-loss Techniques & Products
3.1 Weight-loss Surgery
3.2 Liposuction
3.3 Weight-loss Foods & Drinks
3.4 Diet Centres
3.5 Weight-loss Drugs
4. Obesity Drugs Market
4.1 Market Opportunity Assessment
4.2 Key Weight-loss Drugs
4.2.1 Alli
4.2.1.1 Market Performance
4.2.1.2 Critical Success & Risk Factors
4.2.2 Xenical
4.2.2.1 Market Performance
4.2.2.2 Critical Success & Risk Factors
4.2.3 Acomplia
4.2.3.1 Market Performance
4.2.3.2 Critical Success & Risk Factors
4.2.4 Meridia
4.2.4.1 Market Performance
4.2.4.2 Critical Success & Risk Factors
4.3 Weight-loss Drugs under Clinical Trials
5. Obesity in Developed Markets - A Brief Profile
5.1 US
5.2 Japan
5.3 Germany
5.4 UK
5.5 France
5.6 Italy
5.7 Spain
6. Obesity in Emerging Markets - A Brief Profile
6.1 Russia
6.2 India
6.3 Brazil
6.4 China
7. Critical Success Factors
7.1 Expanding Waistlines
7.2 High Unmet Needs
7.3 Self-Consciousness & Fulfillment
7.4 Strong Pipeline
8. Critical Risk Factors
8.1 High Failure Rate
8.2 High Consumer Demand
8.3 Reimbursement Issues
8.4 Side Effects
9. Key Company Profiles
9.1 Abbott Laboratories
9.2 Roche Holding Ltd
9.3 Sanofi-Aventis
9.4 GlaxoSmithKline plc
9.5 Pfizer Inc.
